SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

# **SCHEDULE 13G**

Under the Securities Exchange Act of 1934 (Amendment No. )\*

# **TCR2** Therapeutics Inc.

(Name of Issuer)

<u>Common Stock, par value \$0.0001 per share</u> (Title of Class of Securities)

<u>87808K106</u>

(CUSIP Number)

<u>February 22, 2022</u> (Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- □ Rule 13d-1(b)
- ý Rule 13d-1(c)
- □ Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 8

SIP I	No. 87808K106			13G	Page 2 of 8 Pages			
1	NAMES OF REPORTING PERSONS							
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)							
	TANG CAPITAL PARTN	ERS, LP						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)							
	(b) ý							
3	SEC USE ONLY							
4	CITIZENSHIP OR PLAC	E OF ORC	ANIZATION					
	DELAWARE							
		5	SOLE VOTIN	G POWER				
			0					
	NUMBER OF	6	SHARED VO	TING POWER				
	SHARES							
	BENEFICIALLY OWNED BY	7	2,800,000	SITIVE POWER				
]	EACH REPORTING	/	SOLE DISPOS	SIIIVE POWER				
	PERSON WITH		0					
		8	SHARED DIS	POSITIVE POWER				
			2,800,000					
9	AGGREGATE AMOUN	NT BENEF	ICIALLY OWNI	ED BY EACH REPORTING PERSON				
	2,800,000							
10		AGGREGA	TE AMOUNT II	N ROW (9) EXCLUDES CERTAIN SHA	ARES			
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9								
	7 20/							
12	7.3% 12 TYPE OF REPORTING PERSON							
	PN							

Page 2 of 8

USIP	No. 87808K106			13G	Page 3 of 8 Pages			
1	NAMES OF REPORTING			SONS (ENTITIES ONLY)				
	TANG CAPITAL MANAGEMENT, LLC							
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) (b)							
3	SEC USE ONLY							
4	CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE							
		5	SOLE VOT	TING POWER				
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		6	SHARED V 2,800,000	VOTING POWER				
		7	SOLE DIS	POSITIVE POWER				
		8	SHARED I 2,800,000	DISPOSITIVE POWER				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,800,000							
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES							
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 7.3%							
12 TYPE OF REPORTING PERSON								
	00							

Page 3 of 8

JSIP No. 87808K106		13G	Page 4 of 8 Pages					
-	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)							
	KEVIN TANG							
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) (b)							
3	SEC USE ONLY							
-	CITIZENSHIP OR PLACE OF ORGANIZATION UNITED STATES							
		5	SOLE VOT	'ING POWER				
	NUMBER OF SHARES BENEFICIALLY	6	SHARED V 2,800,000	/OTING POWER				
E	OWNED BY EACH REPORTING PERSON WITH	7	SOLE DISP	POSITIVE POWER				
		8	SHARED D 2,800,000	DISPOSITIVE POWER				
9	AGGREGATE AMOUN 2,800,000	NT BENEF		NED BY EACH REPORTING PERSON				
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES							
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 7.3%							
12	TYPE OF REPORTING	PERSON						
	μιν							

Page 4 of 8

Item 1(a).		Name of Issuer:						
		CR2 Therapeutics Inc., a Delaware corporation (the "Issuer")						
Item 1(b).		Address of Issuer's Principal Executive Offices:						
		100 Binney Street, Suite 710, Cambridge, MA 02142						
Item 2(a).		Name of Person Filing:						
		This Statement on Schedule 13G (this "Statement") is filed by Tang Capital Partners, LP ("Tang Capital Partners"); Tang Capital Management, LLC, the general partner of Tang Capital Partners ("Tang Capital Management"); and Kevin Tang, the manager of Tang Capital Management.						
Item 2(b).		Address of Principal Business Office or, if none, Residence:						
		4747 Executive Drive, Suite 210, San Diego, CA 92121						
Item 2(c).		Citizenship:						
		Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.						
Item 2(d).		Title of Class of Securities:						
		Common Stock, par value \$0.0001 per share (the "Common Stock")						
Item 2(e).		CUSIP Number: 87808K106						
Item 3. Not a		pplicable.						
Item 4.	Owne	iership.						
	(a)	Amount Beneficially Owned:						
		Tang Capital Partners. Tang Capital Partners beneficially owns 2,800,000 shares of the Issuer's Common Stock.						
		Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.						
		Tang Capital Management. Tang Capital Management beneficially owns 2,800,000 shares of the Issuer's Common Stock.						
		Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.						
		Kevin Tang. Kevin Tang beneficially owns 2,800,000 shares of the Issuer's Common Stock.						
		Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.						

Page 5 of 8

The percentages used herein are based on 38,220,444 shares of Common Stock outstanding as of November 2, 2021, as set forth in the Issuer's Quarterly Report on Form 10-Q that was filed with the Securities and Exchange Commission on November 10, 2021.

(b)	Percent of Class:					
		apital Partners apital Management Tang	7.3% 7.3% 7.3%			
(c)	Numbe	r of shares as to which such person has:				
	(i)	sole power to vote or to direct the vote:				
		Tang Capital Partners Tang Capital Management Kevin Tang	0 shares 0 shares 0 shares			
	(ii)	shared power to vote or to direct the vote:				
		Tang Capital Partners Tang Capital Management Kevin Tang	2,800,000 shares 2,800,000 shares 2,800,000 shares			
	(iii)	sole power to dispose or to direct the disposition of:				
		Tang Capital Partners Tang Capital Management Kevin Tang	0 shares 0 shares 0 shares			
	(iv)	shared power to dispose or to direct the disposition of:				
		Tang Capital Partners Tang Capital Management Kevin Tang	2,800,000 shares 2,800,000 shares 2,800,000 shares			

### Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o

#### Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

#### Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable.

#### Item 8. Identification and Classification of Members of the Group.

Not applicable.

## Item 9. Notice of Dissolution of Group.

Not applicable.

Page 6 of 8

# Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

# SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: March 4, 2022

TANG CAPITAL PARTNERS, LP

By: Tang Capital Management, LLC, its General Partner

By: /s/ Kevin Tang Kevin Tang, Manager

TANG CAPITAL MANAGEMENT, LLC

By: /s/ Kevin Tang Kevin Tang, Manager

/s/ Kevin Tang

Kevin Tang

Page 8 of 8

#### JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, \$0.0001 par value per share, of TCR2 Therapeutics Inc. and further agree to the filing of this Joint Filing Agreement as an exhibit thereto. In addition, each party to this Joint Filing Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G.

Date: March 4, 2022

#### TANG CAPITAL PARTNERS, LP

- By: Tang Capital Management, LLC
- Its: General Partner
- By: /s/ Kevin Tang Name: Kevin Tang Title: Manager

# TANG CAPITAL MANAGEMENT, LLC

By: /s/ Kevin Tang Name: Kevin Tang Title: Manager

/s/ Kevin Tang

Name: Kevin Tang